Form 4: Edwards Lifesciences Executive Equity Grant Disclosure

Annette Bruls, CVP of EMEACLA at Edwards Lifesciences, received equity-based compensation including restricted stock units and options.

Summary

• Annette Bruls, CVP of EMEACLA, was granted 6,650 restricted stock units (RSUs) and 33,700 employee stock options on May 7, 2026.
• The options have an exercise price of $82.76 and vest in four equal annual installments starting May 7, 2027.
• The RSUs vest in four equal annual installments starting one year after the grant date.
• A separate performance-based award of 6,650 target shares was granted, vesting on May 7, 2029, contingent on performance goals.
• 84 shares were withheld on May 8, 2026, to satisfy tax obligations related to the equity grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Equity grants align executive interests with long-term shareholder value creation.
• Performance-based awards incentivize the achievement of specific corporate goals over a three-year period.

Negatives

• The issuance of new equity grants results in potential dilution for existing shareholders.

Risks

• Vesting of performance-based units is subject to the achievement of specific, undisclosed performance goals.
• Market price volatility could impact the ultimate value realized by the executive from these stock options.

Future Outlook

The equity grants are part of the company's long-term incentive program, indicating management's focus on multi-year performance and retention.

Management Comments

• The grants are issued under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program.

Industry Context

StockSavvy.ai notes that equity-based compensation for senior leadership is standard practice in the medical device industry to ensure alignment with long-term strategic growth and shareholder interests.

Comparison to Industry Standards

• The use of a mix of time-vesting options and performance-based restricted stock units is consistent with compensation structures at peer companies like Medtronic and Boston Scientific.
• Four-year vesting schedules are standard for executive equity compensation in the healthcare sector.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new equity.
• Executive leadership is incentivized to maintain long-term company performance.

Next Steps

• Vesting of equity tranches beginning May 7, 2027.
• Evaluation of performance goals for the performance-based restricted stock units maturing in 2029.

Key Dates

Keywords

Edwards Lifesciences, EW, Form 4, Executive Compensation, Equity Grant, Insider Trading, Stock Options